The investment is being made through Compulsory Convertible Cumulative Preference Shares, each priced at ₹29, consistent with the valuation of the recent raise in Series G.
New Delhi: Oravel Stays Ltd, the parent company of OYO, has raised Rs 1,457 crore from a consortium of investors in the latest funding round, sources said. The IPO-bound unicorn has raised nearly Rs 1,040 crore in the Series G funding round. This follows an earlier raise of Rs 416.85 crore in the same series and concludes the round.
Read More: Upcoming IPO: BR Goyal Infrastructure files DRHP for BSE SME IPO. Details here
The IPO-bound unicorn has raised nearly Rs 1,040 crore in the Series G funding round. This follows an earlier raise of Rs 416.85 crore in the same series and concludes the round. According to different documents accessed by PTI, the additional equity issuance was approved by 99.99 per cent shareholders in an EGM held on August 8.
The capital will be used to support OYO’s growth and its global expansion plans, sources said. The additional fund raise values the company at the same valuation of USD 2.4 billion, as the first Series G tranche issued to InCred in July, a source said.
Read More: Hindenburg levels allegations against SEBI Chairperson
The investment is being made through Compulsory Convertible Cumulative Preference Shares, each priced at Rs 29, consistent with the valuation of the recent raise in Series G. The funding round includes contributions from InCred Wealth, who led the recent fundraise as well as J&A Partners, the family office of Mankind Pharma promoters and ASK Financial Holdings.
InCred will be issued 2,62,84,483 shares, J&A Partners 4,13,79,310 shares, ASK Financial up to 48,27,586 shares and Patient Capital Investments Pte Ltd 28,62,06,897 shares. The total additional shares that will be issued is 35,86,98,276, priced at ₹29 per share.
Read More: Adani Group Terms Hindenburg Allegations Malicious, Manipulative of Selective Public Info
This would translate to InCred investing around Rs 76 crore, in addition to the Rs 416.85 crore they recently invested. Serial investor Ashish Kacholia is also investing through InCred. Besides, Patient Capital is investing Rs 830 crore, J&A Partners Rs120 crore, and ASK Rs 14 crore. The Mankind Pharma family is investing through their family office firm J&A Partners, sources said.
The shareholders also approved increasing the company’s authorised share capital from Rs 13,41,13,59,300 to Rs 16,31,13,59,300 in the EGM. The appointment of Sumer Juneja, Managing Partner and Head of EMEA & India at SoftBank Investment Advisors, as a Non-Executive Director on Oravel’s Board was also put up in the EGM and approved with 99.99 per cent votes. Sumer will join Oravel’s Board as a nominee of Softbank Vision Fund.
